Cowen Inc’s Acceleron Pharma XLRN Stock Holding History

Cowen Inc’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-5,411	Closed	-$236K	–	487
2018 Q4	$236K	Buy	+5,411	New	+$270K	0.03%	214

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cowen Inc's XLRN Position: Q1 2019 in Review

Cowen Inc sold out of Acceleron Pharma (XLRN) in Q1 2019, closing a stake of 5,411 shares — an estimated $236K sold.

Cowen Inc first reported a position in XLRN in Q4 2018 and held it in 1 quarter. The position peaked at $236K in Q4 2018. 171 funds tracked by Wall St. Rank hold XLRN as of Q1 2019.

Cowen Inc reported no remaining Acceleron Pharma position as of Q1 2019 after selling out during the quarter.
Cowen Inc sold 5,411 Acceleron Pharma shares in Q1 2019, an estimated $236K.
Cowen Inc first reported a position in Acceleron Pharma in Q4 2018 and held it in 1 quarter.
Cowen Inc's Acceleron Pharma position peaked at $236K in Q4 2018.
171 funds tracked by Wall St. Rank held Acceleron Pharma as of Q1 2019.

Based on Cowen Inc's 13F filing for Q1 2019, filed 14 May 2019.